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Abstract: The statement on Consolidated Standards of Reporting Trials (CONSORT) ensures
transparency in the reporting of randomized trials. However, it is unclear if the statement has
led to improvement in the quality of reporting of tuberculosis (TB) vaccine trials. We explored
the quality of reporting of TB vaccine trials according to the latest version of the CONSORT
statement, released in 2010. We searched PubMed and the Cochrane Central Register of Controlled
Trials in August 2019. We conducted screening, study selection, and data extraction in duplicate;
and resolved differences through discussion. We assessed reporting to be adequate if trials reported
at least 75% of the CONSORT 2010 items. We conducted a trend analysis to assess if there was
improvement in reporting over time. We also used logistic regression to assess factors associated
with adequate reporting. We included 124 trials in the analyses. The mean proportion of adherence
was 67.3% (95% confidence interval 64.4% to 70.1%), with only 46 (37%) trials having adequate
reporting. There was a significant improvement in the quality of reporting over time (p < 0.0001).
Trials published in journals with impact factors between 10 and 20 were more likely to have adequate
reporting (odds ratio 9.4; 95% confidence interval 1.30 to 67.8), compared to lower-impact-factor
journals. Despite advances over time, the reporting of TB vaccine trials is still inadequate and
requires improvement.
Keywords: tuberculosis; CONSORT; randomized trials; vaccine trials; reporting quality
1. Introduction
Tuberculosis (TB) is a bacterial infectious disease which affects mainly the lungs (pulmonary
tuberculosis), but also affects other organs (extra-pulmonary tuberculosis). According to the global TB
report of 2020, TB features among the top 10 causes of death globally [1]. The Bacille Calmette-Guerin
(BCG) vaccine was the first vaccine for TB [2] and it is still the only licensed vaccine for the prevention
of the disease [1]. Although it is efficient in providing immunity against extra-pulmonary TB,
its protection against pulmonary TB has been shown to vary considerably among different individuals
and it is sometimes ineffective [3,4]. Although TB is a treatable disease, the Mycobacterium tuberculosis
bacteria have become resistant to treatment over the years causing drug-resistant TB, including
multidrug-resistant TB and extensively drug-resistant TB [5,6]. This causes a major public health
problem and slows down progress made towards control of TB.
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In ranking clinical research, randomized trials are rated to provide evidence that is more definitive
compared to observational studies. They are the design of choice when conducting medical studies in
which treatment interventions are being compared [7]. Due to concerns on the inadequate reporting
of trials in the 1990s, the Consolidated Standards for Reporting Trials (CONSORT) statement was
developed in 1996 to enhance the quality of trial reporting [8]. CONSORT is a statement consisting of a
checklist, a flow diagram, and narrative text. It has been revised and updated twice, with the latest
revision occurring in 2010 [9,10].
CONSORT has been used to assess the quality of reporting of randomized trials. In an assessment
of the compliance with the CONSORT statement in the reporting head and neck surgery trials in the
top 10 Otolaryngology journals, 182 eligible studies were included in the analysis. Adherence to the
CONSORT ranged from 25.0% to 93.5% with a mean score of 59.0% [11]. The study revealed that
the method of randomization (6.5%), external validity (32.4%), and sample size calculations (40.6%)
were among the areas with the greatest insufficiencies in reporting. A similar study assessing the
reporting quality of trials in the top 10 journals of critical care medicine reported a median score
of 61.1%, with scores of reported items ranging from 33.3% to 86.5%. Items least reported in the
studies were changes to methods after the start of the trial (0.0%), modifications of outcomes after the
trial commences (0.8%), and methods used in supplementary analyses (7.6%) [12]. The two studies
described above were prone to selection bias as the authors limited their search only to top-quality
journals. This selection method also limits the generalizability of their results to trials in the specific
fields covered by the publications.
Certain factors have been associated with better adherence to the CONSORT. A study to assess
adherence and factors influencing adherence to CONSORT in medical oncology showed that journal
citation impact factor, recent publication, and geographic location of studies were independent
predictors of high reporting quality [13]. Similarly, a study evaluating the reporting of trials of sodium
glucose co-transporter 2 inhibitors (an anti-diabetic drug) showed that the journal of publication
and the continent where the trial was conducted were independently associated with the quality of
reporting of trials [14]. The use of only parallel group design trials in this study limited the sample size
of the study which limits the generalizability of the study findings.
A mapping of trials included in Cochrane reviews published from 2011 to 2014 revealed that the use
of CONSORT has led to an overall improvement in reporting over the years [15]. However, the examples
above show that the reporting of trials in specific diseases and in specific journals is still incomplete
and not of utmost standards. Poor reporting of trials can compromise the analysis of a systematic
review and the clinical recommendations made [16]. It makes the trial irreproducible, causing a waste
of resources [17]. The quality of reporting is therefore crucial for better clarity and transparency in the
assessment of study results.
We are not aware of a previous study that has assessed the quality of reporting TB vaccine trials
using the CONSORT statement. Given that TB is a global health problem and that vaccines are an
important way of reducing morbidity and mortality, it is important to assess the quality of reporting
of TB vaccine trials. We assessed the adherence to the CONSORT 2010 statement of TB vaccine
trials published from 1990 to 2018. We hypothesized that studies published after the release of the
CONSORT statement, journal endorsement of CONSORT, non-industrial funding, high impact factor,
and geography would be associated with adequate reporting.
2. Materials and Methods
2.1. Study Design
We conducted a review of the reporting of TB vaccine trials with no restriction to study type
(i.e., superiority, non-inferiority, or equivalence trials). Trials were eligible if they were published
between 1990 and 2018, irrespective of the location where they were conducted. Non-human studies
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and studies not published as full papers (such as conference abstracts) were excluded as they are
unlikely to report all CONSORT items.
2.2. Search and Selection of Studies
With the assistance of the Stellenbosch University health science librarian, we developed and
implemented a comprehensive search in PubMed and the Cochrane Central Register of Controlled
Trials (CENTRAL) on the on the 21st of August 2019. We restricted the search to human studies and to
studies published between January 1990 and December 2018. The details of the search strategy are
shown in Table 1. One researcher (VN) screened the titles and abstracts and excluded irrelevant studies
from the list; after duplicates were removed using study title, authors, and DOI numbers. Two studies
(VN and AM) then independently assessed the full text of potentially eligible studies, as well as selected
studies that met inclusion criteria. Data extraction was conducted independently in duplicate (VN and
AM) using a form adapted from the CONSORT checklist (Appendix A). Discrepancies were discussed
and resolved by consultation with a third researcher (CI). The Cohen’s K statistics [18] for inter-observer
agreement was 0.76. All researchers were trained on research methods and the CONSORT checklist.
Table 1. Search strategy used in the study.
A. Search String Used for the PubMed Database
# Search
1 Tuberculosis OR TB OR PTB
2 Vaccine OR Vaccines OR Vaccination
3 Placebo OR control
4 “randomized controlled trials” OR randomization OR RCT ORcontrolled trials OR Comparative
5
(((Tuberculosis OR TB OR PTB) AND (Vaccine OR Vaccines OR
Vaccination)) AND (Placebo OR control)) AND (“randomized controlled
trials” OR randomization OR RCT OR controlled trials OR Comparative)
6
(((Tuberculosis OR TB OR PTB) AND (Vaccine OR Vaccines OR
Vaccination)) AND (Placebo OR control)) AND (“randomized controlled
trials” OR randomization OR RCT OR controlled trials OR Comparative)
Filters: Humans
7
(((Tuberculosis OR TB OR PTB) AND (Vaccine OR Vaccines OR
Vaccination)) AND (Placebo OR control)) AND (“randomized controlled
trials” OR randomization OR RCT OR controlled trials OR Comparative)
Filters: Humans, from 1990–2020
8
(((Tuberculosis OR TB OR PTB) AND (Vaccine OR Vaccines OR
Vaccination)) AND (Placebo OR control)) AND (“randomized controlled
trials” OR randomization OR RCT OR controlled trials OR Comparative)
Filters: Humans, from 1990–2018
B. Search String Used for the Cochrane Central Register of Controlled Trials
# Search
1 MeSH descriptor: [Tuberculosis] explode all tress
2 MeSH descriptor: [Vaccines] explode all tress
3 MeSH descriptor: [Vaccination] explode all tress
4 #2 OR #3
5 #1 AND #4
2.3. Assessment of Reporting Quality
The assessment was conducted in duplicate by two independent researchers (VN and AM) to
minimize reviewer subjective bias. The CONSORT checklist has 37 items. Item 13c (a flow diagram)
was included as its importance is stressed in the CONSORT explanation and elaborations. The use of the
checklist was piloted on three randomly selected studies by two researchers (VN and AM). Prior to the
data collection, we discussed the meaning and interpretations of the items on the CONSORT list and
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how to judge if the item was reported, unclear or not reported based on the explanations provided
in the CONSORT guidance. A score of 1 was given if an item was reported and 0 if not reported
or if reporting was unclear. Items reported in the supplementary materials of trials were scored as
reported when reference was mentioned in the main article, apart from item 8a as it must be mentioned
in the main article according to the CONSORT explanations and elaborations. Some items were
non-applicable due to the design of the study. We calculated the proportion of the items reported for
each study as “the number of CONSORT items reported” divided by “the total number of CONSORT
items applicable to the study”.
2.4. Explanatory Variables
2.4.1. Journal Endorsement of CONSORT
This was classified into CONSORT endorsing journals (that is, journals requesting authors to
report according to the CONSORT statement) and non-CONSORT endorsing journals.
2.4.2. Funding Type
Funding was categorized as industrial funding, non-industrial funding, and no funding. Industrial
funding included funding from pharmaceutical companies, funding from organizations conducting TB
research, and any other sources of private funding. Funding classified as non-industrial was from the
government and governmental institutions. We assumed that if funding was not mentioned, the study
was not funded. Thus, “no funding” was used when funding was not mentioned or when it was
mentioned that the study was not funded.
2.4.3. Journal Impact Factor
The studies were divided into three categories: impact factor less than 10, impact factor greater
than 10 but less than 20, and impact factor greater than 20. The journal impact factors used were those
of the year when the study was published. A journal impact factor of 10 and above is considered high
in most study fields [19]. The journal impact factor was accessed through the university of Stellenbosch
access to the Journal Citation Reports on the Web of Science group database.
2.4.4. Continent Where the Study Was Conducted
This was the continent from which study participants were recruited. This was divided into the
six continents: (1) Africa, (2) North America, (3) South America, (4) Europe, (5) Asia, and (6) Australia
and New Zealand.
2.4.5. Other Exploratory Variables
We included the year of publication and the number of study centers.
2.5. Outcome Variable
Although the CONSORT statement does not specify what percentage of reported items should be
considered adequate reporting, we defined adequate reporting using the definition used in previous
studies [20,21]. We considered reporting to be adequate in each trial if the trial reported at least 75% of
the items on the CONSORT 2010 checklist applicable to the trial.
2.6. Sample Size Estimation
The number of articles that would have adequate reporting of the CONSORT items was used
for sample size estimation. Assuming that 57% of the studies would have adequate reporting based
on a previous study [21], according to a priori sample size determination, a sample size of 105 was
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required to get a precision of ±10% and a sample size of 128 would give precision of ±9%. In our study,
we obtained a sample of 124 studies.
2.7. Data Analysis
We used STATA statistical software version 16.0 for data analysis (StataCorp, Collage Station,
TX, USA). We summarized categorical variables as count (percent) and continuous variables as
mean (standard deviation). A trend analysis was conducted to assess if there was improvement in
reporting quality over time. We used logistic regression to assess factors associated with adequate
reporting. Characteristics with a p-value < 0.1 in bivariate analyses were entered into a multiple
logistic regression model to determine factors associated with adequate reporting after adjustment for
potential confounding. In the bivariate logistic regression analyses, we assessed the association between
each exploratory variable and the outcome (i.e., adequate reporting). A significance level of 0.1 was
considered as a conservative screen for identifying potential factors associated with adequate reporting
and thus minimize the number of factors that might be excluded in the bivariate analyses. We report
the odds ratio (OR) as a measure of association, with the corresponding 95% confidence interval (CI).
Statistical significance was set at a p-value less than 0.05 in the multiple logistic regression model.
2.8. Ethical Considerations and Reporting
The population of study was published TB vaccine trials, which are publicly available.
Therefore, the study was exempt from ethics approval. The study did not involve direct participation
of human individuals, and as such was of minimal risk and informed consent was not required.
The study was reported in accordance with the preferred reporting items for systematic reviews and
meta-analyses (PRISMA) statement [22].
3. Results
3.1. Study Search and Selection
A total of 1230 reports were obtained from both the PubMed and CENTRAL databases, 469 reports
were retained after the removal of duplicates in Mendeley, 294 reports were excluded after screening
the titles and abstracts, and 51 were excluded after screening the full texts (Figure 1). A total of
124 trials were eligible for data extraction and analysis. These studies were published in six continents;
56 (45%) were published in Africa, 35 (38%) in Europe, 13 (10%) in Asia, 10 (8%) in North America,
8 (7%) in South America, and 2 (2%) in Australia.
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Figure 1. Study flow diagram showing the search and selection process for the study.
3.2. Overall Quality of Reporting
The mean proportion of adherence was 67.3% (95% CI 64.4% to 70.1%), the standard deviation
was 16.2%, and the range was from 26.5% to 97.1%. Forty-six studies (37%) adequately reported the
items of the CONSORT checklist (i.e., reported at least 75% of the items).
Figure 2 shows the proportion of each reported CONSORT item by the 124 studies. The CONSORT
items are explained in Appendix A (Data extraction form Part 2: CONSORT items). The least reported
methodological items were: who generated the random allocation sequence and assigned participants
(16.9%), how the random allocation sequence was generated (37.9%), the type of randomization
(35.5%), the implementation of random allocation sequence (26%), planned interim analysis (13.7%),
and sample size determination (21%). The items adequately reported were scientific background and
rationale (99.2%), specific objectives (96.8%), eligibility criteria (94.4%), pre-specified primary and
secondary outcomes (97.6%), statistical methods (96%), results of primary and secondary outcomes
(100%), and source of funding (81.5%).
Figure 2. Percentage of each Consolidated Standards of Reporting Trials (CONSORT) item reported.
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3.3. Evolution in Reporting Quality
There was a significant improvement in the quality of reporting over time (p < 0.001); 4.4% of
studies published between 1990 and 2000 had adequate reporting, 21.4% of the studies published
between 2001 and 2010 had adequate reporting, and 53.4% of studies published between 2011 and
2018 had adequate reporting.
3.4. Factors Associated with Adequate Reporting
The odds of adequate reporting for studies published in journals with impact factors between
10 and 20 were nine times the odds of studies in journals with impact factors less than 10 (OR 9.4 95%
CI 1.30 to 67.8) (Table 2). The odds of adequate reporting also increased with the year of publication
(p < 0.01). Journal endorsement of the CONSORT statement had a 56% non-significant increase in the
odds of adequate reporting.
Table 2. Study characteristics associated with adequate reporting.
Characteristic Categories Used forthe Characteristic
Crude Odds Ratio *





Impact factor <10 Reference Reference
10 to 20 6.44(1.24 to 33.58) 0.027
9.4
(1.30 to 67.83) 0.026
>20 4.29(1.01 to 18.20) 0.048
2.89
(0.30 to 27.80) 0.35
Type of




(0.12 to 0.65) 0.003
0.55
(0.18 to 1.67) 0.29
No funding 0.09(0.023 to 0.33) <0.001
0.23
(0.45 to 1.26) 0.09
Type of journal Non-CONSORTendorsing Reference Reference
CONSORT endorsing 2.33(1.04 to 5.26) 0.041
1.85
(0.59 to 5.84) 0.28
Year of
publication 1990–2000 Reference Reference
2001–2010 5.99(0.67 to 54.04) 0.110
4.89
(0.38 to 62.45) 0.22
2011–2018 25.24(3.23 to 197.22) 0.002
25.8
(2.25 to 297.20) 0.009
Continent of
study Africa Reference Reference
Asia 0.44(0.12 to 1.61) 0.218
1.45
(0.22 to 9.56) 0.69
Europe 0.52(0.22 to 1.25) 0.144
0.65
(0.22 to 1.93) 0.44
North America
South America 1(0.059 to 16.79) 1.000
0.24
(0.007 to 8.40) 0.43
Number of
centers Single center Reference
Multiple centers 1.344(0.64 to 2.81) 0.432
CI, confidence interval. The crude odds ratios (*) show the results from the bivariate logistic regression analyses,
and adjusted odds ratios (**) show results from the multiple logistic regression analysis. The latter was performed
on all variables in the model.
4. Discussion
We found that the quality of reporting of TB vaccine trials improved significantly with time.
This is in line with several studies that have reported improvement of trial reporting quality over
time [20,22,23]. This could be because authors and editors are becoming more aware of the importance
of adequate reporting and the importance of the CONSORT guideline in reporting trials [24].
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Although there was improvement in the reporting quality of TB vaccine trials over time, the overall
reporting quality was assessed as inadequate as only 37% of the studies had adequate reporting.
Our findings are similar to those reported in a study evaluating the reporting of trials in endodontic
journals. A mean score of 66% was reported, and it was concluded that, although reporting improved
over time, the overall quality of reporting was not adequate [23]. Several other studies conducted in
various medical fields have also demonstrated sub-optimal reporting according to CONSORT [20,24–26].
The reporting of several methodological items was generally poor. The identification of a study as
a randomized trial in the title helps database indexers to be able to index the study correctly in electronic
databases. This eases the online search for trials and prevents studies from being missed in a targeted
search for trials. In this study, up to 78.2% of the studies were not identified as randomized trials in
the title. In addition, sample size determination was one of the least reported items. Poor reporting
of sample size determination has also been reported by other authors [25,27,28]. The calculation of
sample size a priori provides evidence that the study is powered enough to validate any statistically
significant difference observed between the intervention and control groups. It also prevents the
wastage of resources (in over-powered studies) and the needless subjection of participants to possible
harmful interventions.
The generation of random allocation sequence, the type of randomization, implementation
of the random allocation sequence and who generated the allocation sequence are all part of the
randomization process in trials and were poorly reported. Poor reporting of these items has been
shown by other authors [29]. Inadequate information on the randomization process provides room for
doubt in the validity of the study. It causes uncertainty of the randomization process and whether
the sequence was tampered with, introducing selection bias that could lead to an exaggeration of the
treatment effect [30].
Although most of the trials described their studies as blinded and double blinded, the stating
of who was blinded after assignment of the intervention was described only by 43.8% of the studies.
In examining the reporting quality of trials in chiropractic practice, only 46% of the studies published
between 2005 and 2014 reported on blinding [31]. Blinding reduces measurement bias which can be
introduced intentionally or unintentionally as observer bias especially in patient-reported outcomes [32].
Intention-to-treat analysis was reported only in about 60% of the studies. This method of analysis is
usually favored over per-protocol analysis. It reduces the chances of attrition bias that could arise from
non-random loss of study participants that occur from loss-to-follow-up of study participants [33,34]
Very poor reporting of intention-to-treat analysis (12%) in trials of scalp acupuncture treatment for
vascular dementia has also been reported [27].
Some reasons could explain the poor reporting of these items. One reason could be that these
studies are poorly conducted as the quality of reporting has been shown to be related to methodological
quality [35]. However, we have also seen that studies that have been properly conducted with high
methodological quality can be poorly reported [36]. Therefore, poor reporting is not always a reflection
of poor methodological quality.
Another reason could be that studies published before 2010 could be using the old version of the
CONSORT statement published in 1996 [8]. However, even so, they should have placed more emphasis
on the methodological items that are listed as this would increase the validity of their reported studies.
There is also the possibility of word limitation imposed by the journal editors; however, editors could
then provide ways for other information to be made available such as online supplementary material,
hence the main article contains the important methodological aspects.
The type of funding was not associated with the quality of reporting. Similar findings have been
reported by others [31]. This is in contrast with other findings [37,38]. While one suggested that
industrial funding caused researchers to be more meticulous in their methodology [37], the other
concluded that industrial funding could lead to publication bias such that only well-conducted studies
with positive outcomes are published [38].
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Journal endorsement of CONSORT was not associated with adequate reporting. In the evaluation
of the quality of reporting in trials for novel oral anticoagulants in venous thromboembolic disease,
similar findings were reported [39]. Contrasting findings have been reported where journals
endorsing CONSORT had studies with better reporting quality than non-endorsing journals [20,40].
The association of CONSORT endorsement with better reporting quality could be confounded by
citation impact factors [40].
The number of study centers was not associated with the quality of reporting. Other authors have
also found no significant association between the number of study sites and the quality of CONSORT
item reporting [41]. However, another study reported that multicenter studies were statistically
associated with a higher quality of reporting of surgery trials [42].
Studies published in journals with impact factors between 10 and 20 were significantly associated
with adequate reporting but studies published in journals with impact factor above 20 were not
significantly associated with adequate reporting. Journals with high impact factors are more compliant
to the CONSORT as adherence to the CONSORT is a requirement for these journals. A systematic review
on the influence of impact factor on the methodological quality of surgical trials published in journals
with high impact factors was associated with improved methodological quality. However, the impact
factors in this study were only classified as less than 2 or more than 3. Moreover, impact factor in this
study was not independent of industrial funding and positive results outcome, which could both have
been confounding factors [43].
The continent of study was not significantly associated with the quality of reporting. In contrast
to our findings, some studies have reported that studies conducted outside of North America have a
higher quality of reporting [13,14].
5. Strengths and Limitations
A systematic search was applied to obtain all human TB vaccine trials with no limitations except
for human trials and the years of interest. To minimize selection bias, two researchers independently
conducted study selection and data extraction. Discrepancies between the researchers in the study
selection and data extraction were resolved by input from a third researcher.
This study was evaluating the reporting quality of TB vaccine trials published as full papers.
Abstracts, conference papers and unpublished studies were excluded from the study rendering the
study vulnerable to publication bias.
The scoring process used in this study placed equal weight on all the items of the CONSORT list.
We understand that some parts of the CONSORT such as the methodology have been given more
importance. As such, two studies may have the same score, but one may be considered more deficient
if it has poorer reporting of its methodology.
This study was an assessment of the reporting quality of TB vaccine trials and not an assessment
of the methodological quality or if the studies reported were properly conducted. The results of the
various studies were not being analyzed, nor were they being assessed for bias. As such, a study that
could be bias but was well reported was given full credit for its reporting.
6. Conclusions and Recommendations
Our study observed that, although the overall quality of reporting in TB vaccine trials was
inadequate, there was improvement in the quality of reporting with time. These findings do not
discredit the evidence in these studies but serve to enlighten the TB vaccine research community
that more emphasis is needed for appropriate and adequate reporting of studies. This is especially
important as there are still several on-going TB vaccine studies that rely on the evidence being put out
from previous studies. We recommend that journal editors should be more stringent in recommending
that authors should submit a completed CONSORT checklist together with their manuscripts for
publication. We encourage authors to report their methodology in a better manner, especially sample
size determination and the process of randomization and blinding.
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Appendix A. Data Extraction Form




Journal impact factor IF < 10 10 < IF < 20 IF > 20
Continent of trial
Number of trial centers Single center multicenter
Source of funding Industrial Non-industrial No funding
Year of publication 1990–2000 2001–2010 2011–2018
Table A2. Part 2: CONSORT Items.
Section Item No. Checklist Item Yes No Score
Title and
Abstract
1a Identification as a randomized trial in the title
1b Structured summary of trial design, methods, results,and conclusions
Background
and objectives
2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Trial design 3a
Description of trial design (such as parallel, factorial)
including allocation ratio
3b
Important changes to methods after trial
commencement (such as eligibility criteria), with
reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5
The interventions for each group with sufficient
details to allow replication, including how and when
they were actually administered
Outcomes
6a
Completely defined pre-specified primary and
secondary outcome measures, including how and
when they were assessed
6b Any changes to trial outcomes after the trialcommenced, with reasons
Section Item No. Checklist Item Yes No Score
Sample size 7a How sample size was determined
7b When applicable, explanation of any interimanalyses and stopping guidelines
Sequence
generation
8a Method used to generate the random allocationsequence





Mechanism used to implement the random
allocation sequence (such as sequentially numbered
containers), describing any steps taken to conceal the
sequence until interventions were assigned
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Table A2. Cont.
Section Item No. Checklist Item Yes No Score
Implementation 10
Who generated the random allocation sequence, who
enrolled participants, and who assigned participants to
interventions
Blinding 11a
If done, who was blinded after assignment to
interventions (for example, participants, care providers,
those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical
methods
12a Statistical methods used to compare groups for primaryand secondary outcomes
12b Methods for additional analyses, such as subgroupanalyses and adjusted analyses
Participant flow
13a
For each group, the numbers of participants who were
randomly assigned, received intended treatment, and
were analyzed for the primary outcome
13b For each group, losses and exclusions afterrandomization, together with reasons
13c Flow diagram
Recruitment
14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinicalcharacteristics for each group
Numbers
analysed 16
For each group, number of participants (denominator)
included in each analysis and whether the analysis was




For each primary and secondary outcome, results for
each group, and the estimated effect size and its
precision (such as 95% confidence interval)
17b For binary outcomes, presentation of both absolute andrelative effect sizes is recommended
Ancillary
analyses 18
Results of any other analyses performed, including
subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
Harms 19 All-important harms or unintended effects in each group
Limitations 20 Trial limitations, addressing sources of potential bias,imprecision, and, if relevant, multiplicity of analyses
Generalizability 21 Generalizability of the trial findings
Interpretation 22 Interpretation consistent with results, balancing benefitsand harms, and considering other relevant evidence
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support role of funders
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